Icrocaptide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530127

CAS#: 169543-49-1

Description: Icrocaptide, also known as ITF 1697, is a drug potentially for the treatment of acute myocardial infarction.


Chemical Structure

img
Icrocaptide
CAS# 169543-49-1

Theoretical Analysis

MedKoo Cat#: 530127
Name: Icrocaptide
CAS#: 169543-49-1
Chemical Formula: C21H40N8O5
Exact Mass: 484.31
Molecular Weight: 484.6
Elemental Analysis: C, 52.05; H, 8.32; N, 23.12; O, 16.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ITF-1697; ITF1697; ITF 1697

IUPAC/Chemical Name: Glycyl-N(sup 2)-ethyl-L-lysyl-L-prolyl-L-arginine

InChi Key: LPKPGXJXCZNDJO-JYJNAYRXSA-N

InChi Code: InChI=1S/C21H40N8O5/c1-2-28(17(30)13-23)16(8-3-4-10-22)19(32)29-12-6-9-15(29)18(31)27-14(20(33)34)7-5-11-26-21(24)25/h14-16H,2-13,22-23H2,1H3,(H,27,31)(H,33,34)(H4,24,25,26)/t14-,15-,16-/m0/s1

SMILES Code: N=C(N)NCCC[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CCCCN)N(C(CN)=O)CC)=O)CCC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 484.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction).. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J. 2004 Mar;25(5):392-400. PubMed PMID: 15033251.

2: Syeda B, Kiss K, Modarressy K, Schönau K, Schukro C, Derntl M, Laggner A, Sochor H, Glogar D. Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: a randomised, placebo-controlled pilot trial. Drugs R D. 2004;5(3):141-51. PubMed PMID: 15139775.

3: Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, Maruyama S, Bertuglia S, Mascagni P, Goligorsky MS. Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia. Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F713-21. doi: 10.1152/ajprenal.00541.2011. PubMed PMID: 22160777; PubMed Central PMCID: PMC3311315.

4: Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D, Cremonesi P, Bhattacharya J, Mascagni P. ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation. Mol Med. 2007 Nov-Dec;13(11-12):615-24. PubMed PMID: 17948065; PubMed Central PMCID: PMC2034195.

5: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.

6: Di Pierro F, d'Atri G, Marcucci F, Leoni F. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J Pharmacol Toxicol Methods. 1997 Mar;37(2):91-6. PubMed PMID: 9174984.